Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mayne Pharma Group ( (AU:MYX) ) has provided an announcement.
Mayne Pharma Group has disclosed changes in the holdings of director Shawn Patrick O’Brien, reflecting the exercise of performance rights and restricted stock unit (RSU) performance rights under the company’s Performance Rights and Option Plan. Between 16 and 18 December 2025, O’Brien exercised a substantial number of performance rights, resulting in the acquisition of 326,452 ordinary shares and the disposal of 35,170 RSU performance rights and 364,103 performance rights, some through exercise and others forfeited for not meeting vesting conditions, with a portion of the resulting shares sold on-market to cover tax obligations. Following these transactions, O’Brien now holds 568,193 performance rights and 37,041 ordinary shares directly, and 220,532 ordinary shares indirectly through the plan custodian, signalling a shift from derivative-style incentives into a larger direct and indirect equity stake in the company.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is an Australian pharmaceutical company that develops, manufactures and markets branded and generic prescription products. The company operates primarily in specialty and generic medicines, with a focus on regulated markets such as Australia and other international regions, and uses equity-based incentive plans to align management interests with shareholders.
Average Trading Volume: 563,933
Technical Sentiment Signal: Sell
Current Market Cap: A$253.5M
For detailed information about MYX stock, go to TipRanks’ Stock Analysis page.